High Framingham Risk Score Seen for Women With History of Migraine

THURSDAY, Oct. 6, 2022 (HealthDay News) -- High Framingham risk score (FRS) categories are seen among women with a history of migraine, but not for those with active migraine at baseline or during follow-up, according to a study published online Aug. 19 in Neurology.
Khatera Ibrahimi, M.D., from Erasmus MC in Rotterdam, Netherlands, and colleagues used data from a cohort study of 27,539 female health professionals without a history of cardiovascular disease or other major diseases to examine the association between FRS categories and migraine status. Overall, 21,927 women did not report migraine, while 1,500, 3,579, and 533 reported a history of migraine, migraine at baseline, and migraine for the first time during follow-up, respectively.
The researchers found that those with FRS ≥10 percent compared with FRS ≤1 percent had increased odds of the probability of having a history of migraine at baseline (versus never migraine; adjusted odds ratio, 1.76). In contrast, there was an inverse association seen for having FRS ≥10 percent versus FRS ≤1 percent with migraine at baseline and with newly reported migraine during follow-up (odds ratios, 0.64 and 0.42, respectively). A similar inverse association was seen for FRS categories of 5 to 9 and 2 to 4 percent.
"Our results suggest that a relatively healthy vascular system, as assessed by the FRS, is associated with migraine activity status or developing migraine in the future," the authors write. "The biological mechanisms underlying these observations, as well as how our observations might be related to specific cardiovascular disease end points, remain to be studied."
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Health Highlights, Nov. 4, 2021
Supply chain shortages are slowing U.S. health care. Experts say doctors and...
High Sugar Consumption Affects Aging in Childhood Cancer Survivors
MONDAY, Nov. 28, 2022 (HealthDay News) -- Survivors of childhood cancer who...
Convection-Enhanced Delivery of Topotecan Active in Glioblastoma
WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- A subcutaneously implanted,...
Más evidencias de que Uber y Lyft reducen los accidentes por conducción bajo la influencia del alcohol
MARTES, 28 de junio de 2022 (HealthDay News) -- Usar servicios de transporte...
